Primary ovarian leiomyosarcoma as a new component in the nevoid basal cell carcinoma syndrome: a case report.
Renato Seracchioli, Filippo M Colombo, Anna Bagnoli...
https://pubmed.ncbi.nlm.nih.gov/12712116/Actively Recruiting
Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-05-05
30
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are conducting an observational study to collect detailed data on primary ovarian leiomyosarcoma POLMS, a very rare and aggressive type of ovarian cancer. This study includes both past cases diagnosed since 1980 and newly identified cases, aiming to expand knowledge from a previously described group of 113 cases. The goal is to find patterns in diagnosis, treatment, and outcomes to help establish guidelines for managing this rare cancer. The study uses a national, multicenter design with retrospective and prospective data collection. Information is gathered through clinical case reviews and institutional archives, standardized via electronic case report forms on REDCap. The data collected covers patient demographics, tumor features, treatment details including surgery and therapies, recurrence, survival outcomes, and immunohistochemical markers. All information undergoes thorough validation to ensure consistency across centers. Participants provide data through medical records rather than active treatment. Researchers analyze tumor markers like CA-125 and Ki-67, treatment types, and patient outcomes including disease-free and overall survival. The main measurement is the relationship between treatment approaches and prognosis over a 3-year observation period. The study respects patient confidentiality by reporting aggregated results and spans adult female patients aged 18 to 99 years.
CONDITIONS
Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma
V
Vincenzo Dario Mandato, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 years
Participants who undergo routine care are observed to collect data on clinical presentation, treatment details, and outcomes related to primary ovarian leiomyosarcoma.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Renato Seracchioli, Filippo M Colombo, Anna Bagnoli...
https://pubmed.ncbi.nlm.nih.gov/12712116/C C Rasmussen, J S Skilling, J I Sorosky...
https://pubmed.ncbi.nlm.nih.gov/9299270/H D Friedman, M T Mazur
https://pubmed.ncbi.nlm.nih.gov/1929791/Ozgen Solmaz Arslan, Cigdem Sumer, Gulcin Cihangiroglu...
https://pubmed.ncbi.nlm.nih.gov/21061129/R S Azoury, J D Woodruff
https://pubmed.ncbi.nlm.nih.gov/4378308/Tip Pongsuvareeyakul, Kornkanok Sukpan, Somjet Chaicharoen...
https://pubmed.ncbi.nlm.nih.gov/28751996/U Nieminen, C V Numers, E Purola
https://pubmed.ncbi.nlm.nih.gov/5370781/S Dixit, S Singhal, H A Baboo...
https://pubmed.ncbi.nlm.nih.gov/8051647/Meng He, Yan-Jie Deng, Dan-Yi Zhao...
https://pubmed.ncbi.nlm.nih.gov/27073508/P A Nicòtina, F Antico, C Caruso...
https://pubmed.ncbi.nlm.nih.gov/15285319/Azienda USL Reggio Emilia - IRCCS
Lead Sponsor